Biohaven sinks as FDA declines to approve lead drug
Shares of Biohaven (BHVN) plunged ~44% in the premarket on Wednesday after the company said the U.S. FDA issued a Complete Response Letter in response to its marketing application for its lead asset Vyglxia (troriluzole), rejecting the drug's approval....
Seeking Alpha